NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

PROMISE

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Sponsor

Dana-Farber Cancer Institute

Collaborator

Stand Up To Cancer

---

ClinicalTrials.gov Identifier: NCT03689595

Official Title: Predicting Progression of Developing Myeloma in a High